Understanding care needs in lung cancer patients receiving immunotherapy
Quality of Life, Symptom Severity, and Care Needs in Lung Cancer Patients Receiving Immunotherapy
This study looks at lung cancer patients receiving immunotherapy to see how their quality of life and symptoms affect their care needs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06433206 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on lung cancer patients who are undergoing immunotherapy to assess their quality of life, symptom severity, and care needs. It aims to explore the correlations between these factors and identify predictive elements that influence the care requirements of these patients. Conducted at a medical center and a specialized cancer hospital in Taipei City, the study utilizes structured questionnaires and qualitative interviews to gather comprehensive data from participants. A total of 160 patients are included, providing insights into the psychosocial impacts of immunotherapy.
Who should consider this trial
Good fit: Ideal candidates for this study are lung cancer patients aged 20 years or older who have received or are currently receiving immunotherapy.
Not a fit: Patients with significant cognitive impairments or those unable to communicate in Mandarin or Taiwanese may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of care needs for lung cancer patients undergoing immunotherapy, leading to improved patient support and management.
How similar studies have performed: While research on immunotherapy in lung cancer is ongoing, this specific focus on care needs and quality of life is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals diagnosed with malignant lung tumors based on imaging or post-surgical histopathological examination results by specialized physicians. 2. Individuals who have received immunotherapy in the past or are currently undergoing immunotherapy. 3. Research participants who are conscious, aged 20 years or older, able to communicate in Mandarin or Taiwanese, capable of completing the questionnaire, willing to participate in the study, and have signed the research consent form. Exclusion Criteria: 1. Individuals with significant cognitive impairments who are unable to complete the questionnaire. 2. Individuals who are unable to communicate in Mandarin or Taiwanese.
Where this trial is running
Taipei
- National Taiwan University Cancer Center — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Meng Ping Hsiao, master — Ntucc
- Study coordinator: Meng Ping Hsiao, master
- Email: A00708@ntucc.gov.tw
- Phone: +886 919865349
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.